T1	ANAT 201 209	cardiaca
#1	AnnotatorNotes T1	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T2	CHEM 20 34	eritropoyetina
#2	AnnotatorNotes T2	C0014822; Erythropoietin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T3	DISO 72 82	daño renal
#3	AnnotatorNotes T3	C0022660; Kidney Failure, Acute; Disease or Syndrome
T4	ANAT 94 102	cardiaca
#4	AnnotatorNotes T4	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T5	DISO 162 181	fracaso renal agudo
#5	AnnotatorNotes T5	C0022660; Kidney Failure, Acute; Disease or Syndrome
T6	DISO 183 186	FRA
#6	AnnotatorNotes T6	C0022660; Kidney Failure, Acute; Disease or Syndrome
T7	PROC 193 209	cirugía cardiaca
#7	AnnotatorNotes T7	C0018821; Cardiac Surgery procedures; Therapeutic or Preventive Procedure
T8	CHEM 214 241	eritropoyetina recombinante
#8	AnnotatorNotes T8	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T9	PROC 460 464	CABG
#9	AnnotatorNotes T9	C0010055; Coronary Artery Bypass Surgery; Therapeutic or Preventive Procedure (?)
T10	CHEM 652 658	rHuEPO
#10	AnnotatorNotes T10	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T11	PROC 431 458	cirugía de bypass coronario
#11	AnnotatorNotes T11	C0010055; Coronary Artery Bypass Surgery; Therapeutic or Preventive Procedure
T12	PROC 588 615	se asignaron aleatoriamente
#12	AnnotatorNotes T12	C0034656; Randomization; Research Activity
T13	CHEM 660 668	Retacrit
#13	AnnotatorNotes T13	C3642486; Retacrit; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor
T14	PROC 765 773	cuidados
#14	AnnotatorNotes T14	C1947933; care activity; Activity
T15	PROC 939 943	CABG
#15	AnnotatorNotes T15	C0010055; Coronary Artery Bypass Surgery; Therapeutic or Preventive Procedure (?)
T16	PROC 723 730	placebo
#16	AnnotatorNotes T16	C0032042; Placebos; Therapeutic or Preventive Procedure
T17	PROC 735 753	técnica quirúrgica
T18	PROC 1006 1039	niveles de cistatina C plasmática
T19	DISO 837 861	enfermedad renal crónica
#17	AnnotatorNotes T19	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T20	DISO 904 907	ERC
#18	AnnotatorNotes T20	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T21	ANAT 1029 1039	plasmática
#19	AnnotatorNotes T21	C0032105; Plasma; Body Substance
T22	PROC 1285 1289	NGAL
T23	PROC 870 873	FGe
#20	AnnotatorNotes T23	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T24	ANAT 1274 1279	renal
#21	AnnotatorNotes T24	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T25	PROC 560 572	Intervención
#22	AnnotatorNotes T25	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T26	CHEM 1304 1308	urea
#23	AnnotatorNotes T26	C0041942; urea; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T27	ANAT 1309 1320	plasmáticas
#24	AnnotatorNotes T27	C0032105; Plasma; Body Substance
T28	PROC 1323 1351	filtrado glomerular estimado
#25	AnnotatorNotes T28	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T29	DISO 1423 1426	FRA
#26	AnnotatorNotes T29	C0022660; Kidney Failure, Acute; Disease or Syndrome
T30	PROC 1467 1479	intervención
#27	AnnotatorNotes T30	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T31	DISO 1497 1536	eventos adversos atribuibles al fármaco
#28	AnnotatorNotes T31	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T32	CHEM 1529 1536	fármaco
#29	AnnotatorNotes T32	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T33	PROC 1554 1566	intervención
#30	AnnotatorNotes T33	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T34	CHEM 1590 1624	eritropoyetina recombinante humana
#31	AnnotatorNotes T34	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T35	CHEM 1626 1632	rHuEPO
#32	AnnotatorNotes T35	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T36	PROC 1673 1681	prevenir
#33	AnnotatorNotes T36	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T37	DISO 1685 1695	daño renal
#34	AnnotatorNotes T37	C0022660; Kidney Failure, Acute; Disease or Syndrome
T38	PROC 1701 1716	cirugía de CABG
#35	AnnotatorNotes T38	C0010055; Coronary Artery Bypass Surgery; Therapeutic or Preventive Procedure (?)
T39	DISO 1734 1744	daño renal
#36	AnnotatorNotes T39	C0022660; Kidney Failure, Acute; Disease or Syndrome
T40	ANAT 77 82	renal
#37	AnnotatorNotes T40	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T41	CHEM 243 249	rHuEPO
#38	AnnotatorNotes T41	C0376541; Recombinant Erythropoietin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T42	ANAT 170 175	renal
#39	AnnotatorNotes T42	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T43	ANAT 324 331	tisular
#40	AnnotatorNotes T43	C0040300; Body tissue; Tissue | C1284837; Entire body tissue; Tissue
T44	ANAT 449 458	coronario
#41	AnnotatorNotes T44	C0205042; Coronary artery; Body Part, Organ, or Organ Component | C1269008; Entire coronary artery; Body Part, Organ, or Organ Component
T45	PROC 491 557	ensayo clínico controlado, aleatorizado, doble ciego y unicéntrico
T46	CHEM 1017 1028	cistatina C
#42	AnnotatorNotes T46	C0071744; Cystatin C (substance); Amino Acid, Peptide, or Protein · Pharmacologic Substance
T47	ANAT 848 853	renal
#43	AnnotatorNotes T47	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T48	PROC 1114 1126	intervención
#44	AnnotatorNotes T48	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T49	DISO 1269 1279	daño renal
#45	AnnotatorNotes T49	C0022660; Kidney Failure, Acute; Disease or Syndrome
T50	PROC 1291 1301	creatinina
#46	AnnotatorNotes T50	C0201975; Creatinine measurement; Laboratory Procedure
T51	PROC 1304 1320	urea plasmáticas
#47	AnnotatorNotes T51	C0856667; Plasma urea; Laboratory Procedure
T52	PROC 1398 1406	diálisis
#48	AnnotatorNotes T52	C0011946; Dialysis procedure; Therapeutic or Preventive Procedure | C4551529; Renal Dialysis; Therapeutic or Preventive Procedure
T53	ANAT 1690 1695	renal
#49	AnnotatorNotes T53	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T54	ANAT 1739 1744	renal
#50	AnnotatorNotes T54	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T55	Neg_cue 62 68	evitar
T56	Date 83 93	poscirugía
#51	AnnotatorNotes T56	C0032790; Postoperative Period; Temporal Concept
T58	Neg_cue 152 158	evitar
T59	Dose 253 264	dosis altas
#52	AnnotatorNotes T59	C0444956; High dose; Quantitative Concept
T60	PHYS 279 300	efectos pleiotrópicos
#53	AnnotatorNotes T60	C2936488; Genetic Pleiotropy; Genetic Function
T61	LIVB 394 418	pacientes de alto riesgo
#54	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group + C0870646; High Risk Populations; Population Group
T62	LIVB 578 587	pacientes
#55	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T64	Dose 626 648	una dosis única y alta
T65	Dose 697 706	400 UI/kg
T66	Route 711 717	vía IV
#56	AnnotatorNotes T66	C1522726; Intravenous Route of Drug Administration; Functional Concept
T67	LIVB 823 832	pacientes
#57	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T68	Duration 854 861	crónica
#58	AnnotatorNotes T68	C0205191; chronic; Temporal Concept
T71	Date 1043 1064	tercer día poscirugía
T73	LIVB 1105 1126	grupo de intervención
#59	AnnotatorNotes T73	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T76	Neg_cue 1480 1482	no
T78	Dose 1571 1586	una dosis única
T79	Dose 1633 1642	400 UI/kg
T80	Route 1648 1654	vía IV
#60	AnnotatorNotes T80	C1522726; Intravenous Route of Drug Administration; Functional Concept
T81	Neg_cue 1655 1657	no
T82	LIVB 1720 1729	pacientes
#61	AnnotatorNotes T82	C0030705; Patients; Patient or Disabled Group
T83	Date 1745 1758	prequirúrgico
#62	AnnotatorNotes T83	C0445204; Preoperative; Temporal Concept | C2712277; Preoperative Period; Temporal Concept
T57	LIVB 1129 1136	control
#63	AnnotatorNotes T57	C0009932; Control Groups; Group
T63	PHYS 1323 1342	filtrado glomerular
#64	AnnotatorNotes T63	C0232809; Glomerular filtration; Organ or Tissue Function
T69	ANAT 1332 1342	glomerular
#65	AnnotatorNotes T69	C0022663; Kidney Glomerulus; Body Part, Organ, or Organ Component | C1284485; Entire glomerulus; Body Part, Organ, or Organ Component
A1	Assertion T3 Negated
A2	Assertion T5 Negated
A3	Assertion T6 Negated
A4	Assertion T31 Negated
A5	Assertion T36 Negated
A6	Status T19 History_of
A7	Status T20 History_of
T70	Neg_cue 118 120	No
T72	CONC 129 136	métodos
A8	Assertion T72 Negated
#66	AnnotatorNotes T72	C0025663; Methods; Functional Concept
R1	Negation Arg1:T70 Arg2:T72	
T74	Quantifier_or_Qualifier 137 146	adecuados
A9	Assertion T74 Negated
#67	AnnotatorNotes T74	C0205411; Adequate; Qualitative Concept
R2	Has_Quantifier_or_Qualifier Arg1:T72 Arg2:T74	
R3	Negation Arg1:T70 Arg2:T74	
R4	Negation Arg1:T58 Arg2:T5	
R5	Negation Arg1:T76 Arg2:T31	
R6	Negation Arg1:T81 Arg2:T36	
R7	Negation Arg1:T58 Arg2:T6	
R8	Negation Arg1:T55 Arg2:T3	
T75	Neg_cue 1066 1068	No
T77	CONC 1084 1095	diferencias
A10	Assertion T77 Negated
#68	AnnotatorNotes T77	C1705241; Delta (difference); Quantitative Concept
R9	Negation Arg1:T75 Arg2:T77	
T84	Neg_cue 1214 1221	Tampoco
T85	CONC 1234 1245	diferencias
A11	Assertion T85 Negated
#69	AnnotatorNotes T85	C1705241; Delta (difference); Quantitative Concept
R10	Negation Arg1:T84 Arg2:T85	
R11	Location_of Arg1:T40 Arg2:T3	
R12	Overlap Arg1:T3 Arg2:T56	
R13	Before Arg1:T2 Arg2:T3	
R14	Location_of Arg1:T42 Arg2:T5	
R15	Location_of Arg1:T42 Arg2:T6	
R16	After Arg1:T5 Arg2:T7	
R17	Location_of Arg1:T1 Arg2:T7	
R18	Has_Dose_or_Strength Arg1:T41 Arg2:T59	
R19	Has_Dose_or_Strength Arg1:T8 Arg2:T59	
R20	Causes Arg1:T8 Arg2:T60	
R21	Causes Arg1:T41 Arg2:T60	
T86	Observation 313 331	protección tisular
R22	Causes Arg1:T60 Arg2:T86	
T87	Observation 361 368	efectos
#70	AnnotatorNotes T87	C1518681; Outcome of Therapy; Finding (?)
R23	Experiences Arg1:T61 Arg2:T87	
R24	Location_of Arg1:T44 Arg2:T11	
R25	Location_of Arg1:T44 Arg2:T9	
R26	Experiences Arg1:T61 Arg2:T11	
R27	Experiences Arg1:T61 Arg2:T9	
R28	Experiences Arg1:T62 Arg2:T10	
T88	Spec_cue 333 354	Se pretende confirmar
A12	Assertion T87 Speculated
R29	Speculation Arg1:T88 Arg2:T87	
R30	Has_Dose_or_Strength Arg1:T10 Arg2:T64	
R31	Has_Dose_or_Strength Arg1:T13 Arg2:T64	
R32	Experiences Arg1:T62 Arg2:T13	
R33	Has_Dose_or_Strength Arg1:T13 Arg2:T65	
R34	Has_Dose_or_Strength Arg1:T10 Arg2:T65	
R35	Has_Route_or_Mode Arg1:T13 Arg2:T66	
R36	Has_Route_or_Mode Arg1:T10 Arg2:T66	
R37	Experiences Arg1:T62 Arg2:T16	
R38	Experiences Arg1:T67 Arg2:T19	
R39	Location_of Arg1:T47 Arg2:T19	
R40	Has_Duration_or_Interval Arg1:T19 Arg2:T68	
R41	Experiences Arg1:T67 Arg2:T23	
T89	Result_or_Value 874 902	entre 15 y 60 ml/min/1,73 m2
R42	Has_Result_or_Value Arg1:T23 Arg2:T89	
T90	Quantifier_or_Qualifier 908 920	estadio 3A-4
R43	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T90	
R44	Experiences Arg1:T67 Arg2:T20	
R45	Experiences Arg1:T67 Arg2:T15	
R46	Before Arg1:T20 Arg2:T15	
R47	Before Arg1:T23 Arg2:T15	
R48	Before Arg1:T19 Arg2:T15	
R49	Overlap Arg1:T18 Arg2:T71	
R50	Location_of Arg1:T21 Arg2:T18	
R51	Experiences Arg1:T73 Arg2:T48	
R52	Location_of Arg1:T24 Arg2:T49	
R53	Location_of Arg1:T27 Arg2:T51	
R54	Location_of Arg1:T69 Arg2:T28	
R55	Location_of Arg1:T69 Arg2:T63	
T91	CONC 1373 1383	mortalidad
#71	AnnotatorNotes T91	C0026565; Mortality Vital Statistics; Quantitative Concept
T92	CONC 1450 1462	escala RIFLE
#72	AnnotatorNotes T92	[Risk, Injury and Failure]
R56	Overlap Arg1:T30 Arg2:T31	
R57	Causes Arg1:T32 Arg2:T31	
R58	Has_Dose_or_Strength Arg1:T34 Arg2:T78	
R59	Has_Dose_or_Strength Arg1:T35 Arg2:T79	
R60	Has_Route_or_Mode Arg1:T35 Arg2:T80	
R61	Has_Route_or_Mode Arg1:T34 Arg2:T80	
R62	Before Arg1:T36 Arg2:T37	
R63	Location_of Arg1:T53 Arg2:T37	
R64	After Arg1:T37 Arg2:T38	
R65	Experiences Arg1:T82 Arg2:T39	
R66	Location_of Arg1:T54 Arg2:T39	
R67	Overlap Arg1:T39 Arg2:T83	
R68	Used_for Arg1:T34 Arg2:T33	
R69	Used_for Arg1:T35 Arg2:T33	
R71	Experiences Arg1:T82 Arg2:T38	
R72	Experiences Arg1:T82 Arg2:T36	
R74	Experiences Arg1:T82 Arg2:T33	
R73	Used_for Arg1:T33 Arg2:T36	
#73	AnnotatorNotes T22	C5202571; Neutrophil gelatinase-associated lipocalin; Laboratory Procedure
#74	AnnotatorNotes T18	C1619716; Cystatin C measurement; Laboratory Procedure (?)
A13	Experiencer T61 Patient
A14	Experiencer T62 Patient
A15	Experiencer T67 Patient
A16	Experiencer T73 Patient
A17	Experiencer T57 Patient
A18	Experiencer T82 Patient
